Cited by 133Inflammatory Bowel DiseaseOcular Diseases and Behçet’s SyndromeMicroscopic Colitis

Intestinal barrier healing is superior to endoscopic and histologic remission for predicting major adverse outcomes in inflammatory bowel disease: the prospective ERIca trial

Open access
Rath, Timo, Atreya, Raja, Bodenschatz, Julia, Uter, Wolfgang, Geppert, Carol E., Vitali, Francesco, Fischer, Sarah, Waldner, Maximilian J. +3 more·2023·Gastroenterology

Abstract

Background & aims Endoscopic and histologic remission have emerged as key therapeutic goals in the management of inflammatory bowel diseases (IBD) that are associated with favorable long-term disease outcomes. Here, we prospectively compared the predictive value of barrier healing with endoscopic and histologic remission for predicting long-term disease behavior in a large cohort of patients with IBD in clinical remission.Methods At baseline, patients with IBD in clinical remission underwent ileocolonoscopy with assessment of intestinal barrier function by confocal endomicroscopy. Endoscopic and histologic disease activity, as well as barrier healing, was prospectively assessed along established scores. During subsequent follow-up, patients were closely monitored for clinical disease activity and the occurrence of major adverse outcomes (MAOs): disease flares, IBD-related hospitalization or surgery, and initiation or dose escalation of systemic steroids, immunosuppressants, small molecules, or biological therapy.Results The final analysis included 181 patients, 100 with Crohn's disease [CD] and 81 with ulcerative colitis (UC). During a mean follow-up of 35 (CD) and 25 (UC) months, 73% of patients with CD and 69% of patients with UC experienced at least 1 MAO. The probability of MAO-free survival was significantly higher in patients with IBD with endoscopic remission compared with endoscopically active disease. In addition, histologic remission predicted MAO-free survival in patients with UC but not CD. Barrier healing on endomicroscopy was superior to endoscopic and histologic remission for predicting MAO-free survival in both UC and CD.Conclusions Barrier healing is associated with decreased risk of disease progression in patients with clinically remittent IBD, with superior predictive performance compared with endoscopic and histologic remission. Analysis of barrier function might be considered as a future treatment target in clinical trials.Clinicaltrials gov number, NCT05157750.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2022.10.014

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The DNUC algorithm predicted clinical outcomes comparable to physician-assessed endoscopy scores at 12 months (HR for hospitalization, colectomy, steroid use, and relapse of 48.4, 46.4, 10.2, and 8.8, respectively).

    “Similarly, the DNUC algorithm developed by Takenaka et al. predicted clinical outcomes comparable to physician-assessed endoscopy scores at 12 months (HR for hospitalization, colectomy, steroid use, and relapse of 48.4, 46.4, 10.2, and 8.8, respectively).36”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. [5]5. [Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting Therapeutic Targets in In fl ammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-totarget. Am J Gastroenterol 2015;110:1324 -1338.](http://refhub.elsevier.com/S0016-5085(22)01192-1/sref5)

Cited by

Sorted by citations

Authors
Rath, T., Atreya, R., Bodenschatz, J., Uter, W., Geppert, C. E., Vitali, F., Fischer, S., Waldner, M. J., Colombel, J.-F., Hartmann, A., & Neurath, M. F.
Affiliations
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Icahn School of Medicine at Mount Sinai (US)
Corresponding author
Neurath, Markus F.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2023-02
Volume
164
Issue
2
Pages
241-255
ISSN
0016-5085 (ISSN-L)
OpenAlex
W4307055588
Cited by
133
References
60
Citations by year
2026: 36 · 2025: 39 · 2024: 36 · 2023: 21 · 2022: 1
FWCI
14.58
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Deutsche Forschungsgemeinschaft
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
  • Health Sciences › Medicine › Epidemiology › Microscopic Colitis
Keywords
inflammatory bowel disease, confocal laser endomicroscopy, endoscopic remission, histological remission, Crohn's disease, ulcerative colitis, major adverse outcomes, disease flares, immunosuppressants, biologic therapy, disease progression prediction
MeSH terms
Colitis, Ulcerative, Crohn Disease, Humans, Prospective Studies, Remission Induction, Severity of Illness Index, Inflammatory Bowel Diseases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review